Related Experiment Video
Updated: Sep 5, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
An Eleven-microRNA Signature Related to Tumor-Associated Macrophages Predicts Prognosis of Breast Cancer
Sharmilla Devi Jayasingam1, Marimuthu Citartan2, Anani Aila Mat Zin3
1Department of Clinical Medicine, Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia, Kepala Batas 13200, Penang, Malaysia.
Abstract:
The dysregulation of microRNAs (miRNAs) has been known to play important roles in tumor development and progression. However, the understanding of the involvement of miRNAs in regulating tumor-associated macrophages (TAMs) and how these TAM-related miRNAs (TRMs) modulate cancer progression is still in its infancy. This study aims to explore the prognostic value of TRMs in breast cancer via the construction of a novel TRM signature. Potential TRMs were identified from the literature, and their prognostic value was evaluated using 1063 cases in The Cancer Genome Atlas Breast Cancer database. The TRM signature was further validated in the external Gene Expression Omnibus GSE22220 dataset. Gene sets enrichment analyses were performed to gain insight into the biological functions of this TRM signature. An eleven-TRM signature consisting of mir-21, mir-24-2, mir-125a, mir-221, mir-22, mir-501, mir-365b, mir-660, mir-146a, let-7b and mir-31 was constructed. This signature significantly differentiated the high-risk group from the low-risk in terms of overall survival (OS)/ distant-relapse free survival (DRFS) (p value < 0.001). The prognostic value of the signature was further enhanced by incorporating other independent prognostic factors in a nomogram-based prediction model, yielding the highest AUC of 0.79 (95% CI: 0.72−0.86) at 5-year OS. Enrichment analyses confirmed that the differentially expressed genes were mainly involved in immune-related pathways such as adaptive immune response, humoral immune response and Th1 and Th2 cell differentiation. This eleven-TRM signature has great potential as a prognostic factor for breast cancer patients besides unravelling the dysregulated immune pathways in high-risk breast cancer.
Insights
This study identifies an eleven-microRNA (miRNA) signature that predicts breast cancer patient outcomes. This tumor-associated miRNA signature effectively differentiates high-risk from low-risk patients, aiding in prognosis.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- MicroRNA (miRNA) dysregulation is implicated in cancer development.
- The role of TAM-related miRNAs (TRMs) in breast cancer progression is not well understood.
- Novel prognostic markers are needed for breast cancer.
Purpose of the Study:
- To explore the prognostic value of TRMs in breast cancer.
- To construct and validate a novel TRM signature for breast cancer prognosis.
Main Methods:
- TRMs were identified from literature.
- A TRM signature was constructed using The Cancer Genome Atlas (TCGA) breast cancer data (n=1063).
- The signature was validated using the Gene Expression Omnibus (GEO) GSE22220 dataset.
- Gene set enrichment analyses were performed.
Main Results:
- An eleven-TRM signature (including miR-21, miR-24-2, miR-125a, miR-221, miR-22, miR-501, miR-365b, miR-660, miR-146a, let-7b, miR-31) was constructed.
- This signature significantly predicted overall survival (OS) and distant-relapse free survival (DRFS) (p < 0.001).
- A nomogram incorporating the signature achieved an AUC of 0.79 for 5-year OS.
- Enrichment analyses revealed involvement in immune-related pathways.
Conclusions:
- The eleven-TRM signature demonstrates significant prognostic value for breast cancer patients.
- This signature can enhance risk prediction when combined with other prognostic factors.
- The findings shed light on dysregulated immune pathways in high-risk breast cancer.
Related Concept Videos
The Tumor Microenvironment
MicroRNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

